Middle East conflict impact on ROW business
Saudi Arabia shipments paused due to geopolitical tensions, causing a dip in ROW revenue; recovery uncertain.
GLAND / Q4-FY26 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Raw material cost inflation from glass/solvent
Suppliers requesting 5-6% price increase for vials/glass; potential 1-2% impact on overall costs.
GLP-1 revenue timing uncertainty
Management excludes GLP-1 from guidance due to dependency on partner approvals and market launches, creating upside risk but also uncertainty.
Cenexi revenue growth may lag expectations
Despite capacity additions, Cenexi revenue growth may be modest in FY27 as new lines ramp up slowly; focus on profitability over top line.